Preferred Label : Anti-EGFR/Anti-4-1BB Bispecific Antibody HLX35;
NCIt synonyms : EGFR x 4-1BB Bispecific Antibody HLX35; Anti-EGFR/4-1BB Bispecific Antibody HLX35;
NCIt definition : A recombinant human bispecific antibody targeting both the tumor-associated antigen
(TAA) epidermal growth factor receptor (EGFR) and the costimulatory receptor 4-1BB
(CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential
checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration,
anti-EGFR/anti-4-1BB bispecific antibody HLX35 simultaneously targets and binds to
the extracellular domain of EGFR, which is expressed on a variety of tumor cells and
4-1BB, which is expressed on activated T-lymphocytes, natural killer (NK) cells and
NK-T-cells. This crosslinks EGFR-expressing tumor cells and 4-1BB-expressing T-cells.
The binding to EGFR inactivates EGFR and prevents EGFR-mediated signaling. Through
4-1BB binding, HLX35 acts as a conditional 4-1BB agonist, resulting in cytotoxic T-cell
co-stimulation and enhances T-lymphocyte-mediated anti-tumor activity. It also activates
memory T-cells, NK cells and dendritic cells (DCs) in the tumor microenvironment (TME).
This activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated
lysis in EGFR-expressing tumor cells. 4-1BB, a surface glycoprotein of the tumor necrosis
factor receptor superfamily, is an inducible costimulatory receptor that plays a key
role in T-cell proliferation, survival and cytolytic activity. EGFR, belonging to
the receptor tyrosine kinases family and upregulated or mutated in a variety of tumor
cell types, plays a key role in tumor cell proliferation.;
Molecule name : HLX-35; BNA-035; BNA 035; HLX 35;
NCI Metathesaurus CUI : CL1792373;
Origin ID : C187697;
UMLS CUI : C5706439;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
